Brokerages Expect Kiniksa Pharmaceuticals Ltd (KNSA) to Post -$0.74 EPS

Share on StockTwits

Wall Street brokerages expect Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) to announce ($0.74) earnings per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Kiniksa Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.85) and the highest estimate coming in at ($0.62). The firm is scheduled to announce its next quarterly earnings report on Thursday, February 7th.

On average, analysts expect that Kiniksa Pharmaceuticals will report full year earnings of ($2.63) per share for the current year, with EPS estimates ranging from ($2.83) to ($2.42). For the next financial year, analysts expect that the firm will report earnings of ($3.08) per share, with EPS estimates ranging from ($3.42) to ($2.74). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that follow Kiniksa Pharmaceuticals.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Thursday, November 1st. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.03.

Several equities research analysts recently issued reports on KNSA shares. Zacks Investment Research upgraded shares of Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a research note on Wednesday. Wedbush reiterated an “outperform” rating and issued a $31.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, September 11th. Finally, JMP Securities raised their target price on shares of Kiniksa Pharmaceuticals from $33.00 to $44.00 and gave the company an “outperform” rating in a research note on Monday, September 17th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $31.75.

Shares of NASDAQ:KNSA opened at $19.94 on Friday. Kiniksa Pharmaceuticals has a 52-week low of $13.04 and a 52-week high of $32.88.

Large investors have recently modified their holdings of the stock. Hillhouse Capital Management Ltd. bought a new position in Kiniksa Pharmaceuticals in the 2nd quarter valued at about $99,529,000. Baker BROS. Advisors LP bought a new position in Kiniksa Pharmaceuticals in the 2nd quarter valued at about $52,050,000. Boxer Capital LLC bought a new position in Kiniksa Pharmaceuticals in the 2nd quarter valued at about $20,346,000. FMR LLC bought a new position in Kiniksa Pharmaceuticals in the 2nd quarter valued at about $14,565,000. Finally, VHCP Management II LLC bought a new position in Kiniksa Pharmaceuticals in the 2nd quarter valued at about $11,091,000. Institutional investors and hedge funds own 34.91% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

Recommended Story: What is a Stop Order?

Get a free copy of the Zacks research report on Kiniksa Pharmaceuticals (KNSA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply